Author details

Full Name

Yongmei Feng

Affiliation

Cancer Center, Sanford Burnham Prebys Medical Discovery Institute

ORCID

Career Start Year

2002

Papers

H Index

Expertise

CM4AI Collaborator

Trey Ideker (CM4AI)

PMID	Paper Title	Journal Title	Published Year
37406115	Melanoma-intrinsic NR2F6 activity regulates antitumor immunity.	Sci Adv	2023
36050469	NRF2 mediates melanoma addiction to GCDH by modulating apoptotic signalling.	Nat Cell Biol	2022
35524561	P-TEFb is degraded by Siah1/2 in quiescent cells.	Nucleic Acids Res	2022
35561126	Arginyl-tRNA-protein transferase 1 (ATE1) promotes melanoma cell growth and migration.	FEBS Lett	2022
36532738	Inhibition of coronavirus HCoV-OC43 by targeting the eIF4F complex.	Front Pharmacol	2022
34518534	The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors.	Nat Commun	2021
33632871	Identification and Characterization of IMD-0354 as a Glutamine Carrier Protein Inhibitor in Melanoma.	Mol Cancer Ther	2021
32360601	Regulation of eIF2Î± by RNF4 Promotes Melanoma Tumorigenesis and Therapy Resistance.	J Invest Dermatol	2020
32049008	Prebiotic-Induced Anti-tumor Immunity Attenuates Tumor Growth.	Cell Rep	2020
31911617	Siah2 control of T-regulatory cells limits anti-tumor immunity.	Nat Commun	2020
31733993	Lineage-Restricted Regulation of SCD and Fatty Acid Saturation by MITF Controls Melanoma Phenotypic Plasticity.	Mol Cell	2020
33219123	Chemical mutagenesis of a GPCR ligand: Detoxifying "inflammo-attraction" to direct therapeutic stem cell migration.	Proc Natl Acad Sci U S A	2020
32571981	SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth.	Mol Cancer Res	2020
32641491	PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity.	Sci Transl Med	2020
32839770	SARS-CoV-2 ORF9c Is a Membrane-Associated Protein that Suppresses Antiviral Responses in Cells.	bioRxiv	2020
31021236	Improving CRISPR-Cas9 Genome Editing Efficiency by Fusion with Chromatin-Modulating Peptides.	CRISPR J	2019
31740775	Translational reprogramming marks adaptation to asparagine restriction in cancer.	Nat Cell Biol	2019
30771432	Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells.	Cancer Lett	2019
29227283	SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth.	J Clin Invest	2018
30209241	Targeting the Warburg effect via LDHA inhibition engages ATF4 signaling for cancer cell survival.	EMBO J	2018
28387220	Targeted activation of diverse CRISPR-Cas systems for mammalian genome editing via proximal CRISPR targeting.	Nat Commun	2017
34541154	Improving CRISPR Gene Editing Efficiency by Proximal dCas9 Targeting.	Bio Protoc	2017
25728676	Transcriptional repression of IFNÎ²1 by ATF2 confers melanoma resistance to therapy.	Oncogene	2015
26603897	SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.	Cancer Res	2015
26645581	The transcription factor ATF2 promotes melanoma metastasis by suppressing protein fucosylation.	Sci Signal	2015
26027934	Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation.	Cell Rep	2015
25712345	PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets.	Cancer Res	2015
25759021	Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies.	Cancer Cell	2015
24037523	Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma.	Oncogene	2014
24891602	Actin and dynamin2 dynamics and interplay during clathrin-mediated endocytosis.	J Cell Biol	2014
23035722	Inhibition of melanoma development in the Nras((Q61K)) ::Ink4a(-/-) mouse model by the small molecule BI-69A11.	Pigment Cell Melanoma Res	2013
23891150	Structure-based design of covalent Siah inhibitors.	Chem Biol	2013
23666368	Development of a novel class of tubulin inhibitors with promising anticancer activities.	Mol Cancer Res	2013
23608534	Degradation of newly synthesized polypeptides by ribosome-associated RACK1/c-Jun N-terminal kinase/eukaryotic elongation factor 1A2 complex.	Mol Cell Biol	2013
23790042	Synthesis and SAR studies of dual AKT/NF-ÎºB inhibitors against melanoma.	Chem Biol Drug Des	2013
23589174	Inhibition of melanoma growth by small molecules that promote the mitochondrial localization of ATF2.	Clin Cancer Res	2013
21592316	Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-ÎºB pathways.	Pigment Cell Melanoma Res	2011
19819692	Design and synthesis of a simplified inhibitor for XIAP-BIR3 domain.	Bioorg Med Chem Lett	2009
17389615	Haploinsufficiency of the cdc2l gene contributes to skin cancer development in mice.	Carcinogenesis	2007
16481740	Increased gene copy number of the transcription factor E2F1 in malignant melanoma.	Cancer Biol Ther	2006
15656972	Isolation and characterization of the human Cdc2L1 gene promoter.	Gene	2005
16203664	New developments in the staging of melanoma.	Cancer Invest	2005
15883043	The cyclin-dependent kinase 11 interacts with 14-3-3 proteins.	Biochem Biophys Res Commun	2005
16004605	Death-signal-induced relocalization of cyclin-dependent kinase 11 to mitochondria.	Biochem J	2005
15087126	Identification and characterization of the human Cdc2l2 gene promoter.	Gene	2004
12446680	The p34cdc2-related cyclin-dependent kinase 11 interacts with the p47 subunit of eukaryotic initiation factor 3 during apoptosis.	J Biol Chem	2003
12115485	Analysis of mutations and identification of several polymorphisms in the putative promoter region of the P34CDC2-related CDC2L1 gene located at 1P36 in melanoma cell lines and melanoma families.	Int J Cancer	2002

1 - 47 of 47

Shruthy Suresh

Memorial Sloan Kettering Cancer Center

Career Start Year 2013

Number of shared co-authors 1

Thibault Houles

Institute for Research in Immunology and Cancer (IRIC), Universite de Montreal

Career Start Year 2011

Number of shared co-authors 0

Frederick S Vizeacoumar

College of Medicine, University of Saskatchewan

Career Start Year 2010

Number of shared co-authors 1

Cristina Ivan

The University of Texas MD Anderson Cancer Center

Career Start Year 2010

Number of shared co-authors 2

Guo Chen

China Pharmaceutical University

Career Start Year 2009

Number of shared co-authors 9

Nina Fenouille

Universite Paris Cite, INSERM, CNRS

Career Start Year 2008

Number of shared co-authors 0

Shweta Joshi

Moores Cancer Center, University of California

Career Start Year 2007

Number of shared co-authors 1

Young K Song

National Cancer Institute, National Institutes of Health

Career Start Year 2007

Number of shared co-authors 0

Yi-Hung Ou

The First Affiliated Hospital of Guangdong Pharmaceutical University

Career Start Year 2005

Number of shared co-authors 1

Genevi??ve Lavoie

Institute for Research in Immunology and Cancer (IRIC)

Career Start Year 2004

Number of shared co-authors 1

Xiaohu Zhang

National Center for Advancing Translational Sciences

Career Start Year 2003

Number of shared co-authors 1

Aleksandra A Pandyra

Hematology and Clinical Immunology, Heinrich-Heine University Dusseldorf

Career Start Year 2003

Number of shared co-authors 1

Andrew V Kossenkov

The Wistar Institute

Career Start Year 2003

Number of shared co-authors 9

Daniel Zingg

Netherlands Cancer Institute

Career Start Year 2001

Number of shared co-authors 3

Yong Jae Shin

Cancer Stem Cell Research Center, Samsung Biomedical Research Institute

Career Start Year 2001

Number of shared co-authors 0

Fan Yang

West China Second Hospital, Sichuan University

Career Start Year 2000

Number of shared co-authors 0

Jianjun Shen

The University of Texas MD Anderson Cancer Center

Career Start Year 1998

Number of shared co-authors 5

Jun Yao

The University of Texas MD Anderson Cancer Center

Career Start Year 1997

Number of shared co-authors 1

Dongquan Chen

University of Alabama at Birmingham

Career Start Year 1997

Number of shared co-authors 0

Andrew E Aplin

Thomas Jefferson University

Career Start Year 1996

Number of shared co-authors 12

Goutham Narla

The University of Michigan Medical School ann arbor

Career Start Year 1995

Number of shared co-authors 2

John Alan Diehl

Case Western Reserve University School of Medicine

Career Start Year 1993

Number of shared co-authors 5

Ashani T Weeraratna

Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine

Career Start Year 1992

Number of shared co-authors 11

Wei Zhang

The University of Texas MD Anderson Cancer Center

Career Start Year 1988

Number of shared co-authors 1

William C Hahn

Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute

Career Start Year 1987

Number of shared co-authors 7

Lori S Hart

Children's Hospital of Philadelphia, USA. [2] Center for Childhood Cancer Research

Career Start Year 1987

Number of shared co-authors 3

Rakesh Kumar

Rutgers New Jersey Medical School

Career Start Year 1987

Number of shared co-authors 6

Daniel S Peeper

Netherlands Cancer Institute

Career Start Year 1987

Number of shared co-authors 5

David E Fisher

Cutaneous Biology Research Center, Mass. General Hospital, Harvard Medical School

Career Start Year 1983

Number of shared co-authors 13

Francisca Vazquez

Broad Institute of MIT and Harvard

Career Start Year 1979

Number of shared co-authors 1

row(s) 1 - 30 of 30

Ze'ev Ronai

Cancer Center, Sanford Burnham Prebys Medical Discovery Institute

Co-authored papers 30

Hyungsoo Kim

Sungkyunkwan University

Co-authored papers 8

Eric Lau

Moffitt Cancer Center

Co-authored papers 7

Marcus Bosenberg

Yale School of Medicine

Co-authored papers 6

Marzia Scortegagna

NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute

Co-authored papers 6

Eytan Ruppin

National Cancer Institute

Co-authored papers 6

Ivan Topisirovic

McGill University

Co-authored papers 6

David A Scott

Sanford Burnham Prebys Medical Discovery Institute

Co-authored papers 5

Rabi Murad

Sanford Burnham Prebys Medical Discovery Institute

Co-authored papers 4

Harriet M Kluger

Yale School of Medicine

Co-authored papers 4

Meenhard Herlyn

Ellen and Ronald Caplan Cancer Center, The Wistar Institute

Co-authored papers 4

Brian James

Cancer Center, Sanford Burnham Prebys Medical Discovery Institute

Co-authored papers 4

Reinhard Dummer

University Hospital Zurich

Co-authored papers 3

Andrei L Osterman

Sanford Burnham Prebys Medical Discovery Institute

Co-authored papers 3

Anthony B Pinkerton

Sanford Burnham Prebys Medical Discovery Institute

Co-authored papers 3

Eduard Sergienko

Cancer Center, Sanford Burnham Prebys Medical Discovery Institute

Co-authored papers 3

Pedro Aza-Blanc

Sanford-Burnham-Prebys Medical Discovery Institute

Co-authored papers 3

Tal Varsano

Sanford-Burnham Medical Research Institute

Co-authored papers 2

Sumit K Chanda

The Scripps Research Institute

Co-authored papers 2

Michael A Davies

The University of Texas MD Anderson Cancer Center

Co-authored papers 2

Giuseppina Claps

Institut National de la Sante et de la Recherche Medicale (INSERM) U

Co-authored papers 2

Stan Krajewski

Cellstan-Immunoquant Inc.

Co-authored papers 2

Aniruddha J Deshpande

Sanford Burnham Prebys Medical Discovery Institute

Co-authored papers 2

Chen-Ting Ma

Sanford Burnham Prebys Medical Discovery Institute

Co-authored papers 2

Gao Zhang

Co-authored papers 2

Mitchell P Levesque

University Hospital Zurich

Co-authored papers 2

Susanne Heynen-Genel

Cancer Center, Sanford Burnham Prebys Medical Discovery Institute

Co-authored papers 2

Christian A Hassig

Sanford Burnham Prebys Medical Discovery Institute

Co-authored papers 2

Ian Pass

Cancer Center, Sanford Burnham Prebys Medical Discovery Institute

Co-authored papers 2

Fu-Yue Zeng

Sanford Burnham Prebys Medical Discovery Institute

Co-authored papers 1

1 - 30

Author Details

Column Actions

Recommended Authors

Collaborators